Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: Update on a 2-year double-blind multicentre study

Journal of Neural Transmission, Supplement

Volumn , Issue 54, 1998, Pages 301-310

  Gutzmann, H ^a   Hadler, D ^b,c  

^a Vivantes Klinikum Hellersdorf   (Germany)

^b Takeda Europe   (Germany)

^c Takeda Europe   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IDEBENONE; ANTIOXIDANT; BENZOQUINONE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME; ADULT; AGED; DOSE RESPONSE; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; TIME;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIOXIDANTS; BENZOQUINONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS;

EID: 0031593616     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-7508-8_30     Document Type: Article

References (20)

1. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd ed, rev. APA, Washington, DC
2. CPMP Working Party on Efficacy of Medicinal Products (1992) Antidementia medicinal products. Note for guidance (Draft 5). Commission of the European Communities, Brussels
3. Erzigkeit H (1989) SKT: Ein Kurztest zur Erfassung von Gedächtnis- und Aufmerksamkeitsstörungen (4th ed.) [SKT: A short test to assess impairment of memory and attention]. Beltz Test, Weinheim
4. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198
5. Gutzmann H, Hadler D, Erzigkeit H (1997) Long-term treatment of Alzheimer's disease with idebenone. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewki HM (eds) Alzheimer's disease: biology, diagnosis and therapeutics. John Wiley & Sons, New York, pp 687-705
6. Hachinski VC, Illiff LD, Zihlka E, DuBoulay GH, McAllister VL, Marshall R, Ross-Russell RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32: 632-637
7. Kanowski S, Ladurner G, Maurer K, Oswald WD, Stein U (1990) Empfehlungen zur Evaluierung der Wirksamkeit von Nootropika. Z Gerontopsychol-psychiatr 3: 67-79
8. Kern U, Menges K (1992) Proof of efficacy of nootropics for the indication "dementia" (Phase III) - Recommendations. Pharmacopsychiatry 25: 126-135
9. Leber P (1996) Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 10 [Suppl 1]: 31-35
10. Lienert GA (1967) Testaufbau und Testanalyse, 2nd ed. [Test construction and test analysis]. Beltz, Weinheim
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department Health & Human Services Task Force on Alzheimer's disease. Neurology 34: 939-944
12. National Institute of Mental Health (1976) Clinical Global Impressions. In: Guy W (ed) EDCEU assessment manual for psychopharmacology, rev ed. NIMH, Rockville, MD, pp 217-222
13. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer's disease. Am J Psychiatry 141: 1356-1364
14. Sano M, et al (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336: 1216-1222
15. Senin U, Parnetti L, Barbagallo-Sangiorgi G, Bartorelli L, Bocola V, Capurso A, Cuzzupoli M, Denario M, Marigliano V, Tammaro A, Fioravanti M (1992) Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr 15: 249-260
16. Spiegel R, Brunner C, Ermini-Fünfschilling D, Monsch A, Notier M, Puxty J, Tremmel L (1991) A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients). J Am Geriatr Soc 39: 339-347
17. Weyer G, Ihl R, Mohs RC, Schambach M, Denkel A, Kaiser-Kehl H (1993) Validierungsuntersuchungen zu einer deutschen Version der Alzheimer's Disease Assessment Scale ADAS [Investigations on the validity of a German version of the Alzheimer's Disease Assessment Scale ADAS]. Z Gerontopsychol-psychiatr 6: 67-81
18. Weyer G, Erzigkeit H, Hadler D, Kubicki S (1996) Efficacy and safety of idebenone in the long-term treatment of Alzheimer's disease: a double-blind, placebo-controlled multicentre study. Hum Psychopharmacol 11: 53-65
19. Weyer G, Babej-Dölle RM, Hadler D, Hofmann S, Herrmann W (1997) A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 11: 340-350
20. World Medical Association (1989) Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects (Amended by the 41st World Medical Assembly, Hong Kong, September 1989)